Meloxicam: selective COX-2 inhibition in clinical practice (Q39455254)

12 September 2017

1 reference

title

Meloxicam: selective COX-2 inhibition in clinical practice (English)

1 reference

12 September 2017

1 reference

ChEBI release 2020-05-28

D E Furst

1

1 reference

12 September 2017

publication date

1 June 1997

1 reference

Seminars in Arthritis and Rheumatism

12 September 2017

published in

1 reference

12 September 2017

volume

26

1 reference

12 September 2017

issue

6 Suppl 1

1 reference

12 September 2017

page(s)

21-27

1 reference

Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

Safety of meloxicam: a global analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

Safety evaluation of nabumetone in United States clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

Meloxicam: metabolic profile and biotransformation products in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

A review of the clinical pharmacokinetics of meloxicam

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

The effect of etodolac administration on renal function in patients with arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980049-2

7 January 2021

10.1016/S0049-0172(97)80049-2

Identifiers

DOI

1 reference

12 September 2017

1 reference